Update for European Achondroplasia Associations 8 April 2020 BioMarin is providing this statement to provide general information about the company's clinical development program for achondroplasia in the context of the COVID-19 (Coronavirus) pandemic. "As more cases of COVID-19 are confirmed, we recognize the increased challenges and concerns faced by participants in the BioMarin clinical studies. The safety and well-being of study participants, healthcare providers, and our communities is par […]

Pfizer is pausing for three weeks the recruitment portion of the company's new and ongoing global interventional clinical studies.

QED is actively assessing the impact that COVID-19 may have on the work in place and wants to assure patients and families that they are committed to moving forward with the program to develop Infigratinib as an option for children with achondroplasia. 

A partnership between a patient organization with a textile professional from the north of Portugal is heading to create a clothing line for people with bone dysplasias/short stature.

There are more than 7000 languages in the world, but we need the be able to read and understand the same document when this is translated. We have supported a multinational project on validating the linguistic aspects of a questionnaire on achondroplasia in 15 countries.

The largest European population-based epidemiological study on achondroplasia was published with data provided by 28 registries in Europe, with cases reported between 1991-2015.